Research graph
References from Cardiovascular Risk in Psoriatic Arthritis in the Treat-to-Target Era: A Focused Expert Narrative Review of Epidemiology, Risk Assessment, Vascular Imaging, and Prevention. Local targets link to admitted publications; unresolved targets remain external evidence.
Psoriatic arthritis
10.1038/s41572-021-00293-y · 2021 · External reference
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update
10.1136/ard-2024-225531 · 2024 · External reference
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Updated treatment recommendations for psoriatic arthritis 2021
10.1038/s41584-022-00798-0 · 2022 · External reference
Comorbidities in psoriatic arthritis: A systematic review and meta-analysis
10.1007/s00296-020-04775-2 · 2021 · External reference
Cardiovascular comorbidities in patients with psoriatic arthritis: A systematic review
10.1136/annrheumdis-2011-201194 · 2013 · External reference
Cardiovascular comorbidities in psoriatic arthritis: State of the art
10.1177/1759720x241274537 · 2024 · External reference
Cardiovascular risk in psoriatic arthritis: How can we manage it?
10.1016/j.autrev.2025.103889 · 2025 · External reference
10.3390/ijms27104226
10.3390/ijms27104226 · External reference
SANRA—A scale for the quality assessment of narrative review articles
10.1186/s41073-019-0064-8 · 2019 · External reference
Cardiovascular morbidity in psoriatic arthritis
10.1136/ard.2008.094839 · 2009 · External reference
Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: A population-based cohort study
10.1136/annrheumdis-2014-205675 · 2015 · External reference
Risk of cardiovascular morbidity in patients with psoriatic arthritis: A meta-analysis of observational studies
10.1002/acr.22926 · 2017 · External reference
Incidence and predictors for cardiovascular events in patients with psoriatic arthritis
10.1136/annrheumdis-2015-207980 · 2016 · External reference
Risk of cardiovascular disease decreases over time in psoriatic arthritis but not in spondylarthritis: Meta-analysis of longitudinal studies
10.1093/rheumatology/keae080 · 2024 · External reference
Patterns and risk of cardiovascular disease in rheumatoid arthritis and psoriatic arthritis: A nationwide cohort study in the UK
10.1093/rap/rkag016 · 2026 · External reference
Excess cardiovascular morbidity in psoriatic arthritis and cardioprotective effects of biologic DMARDs: A propensity-matched analysis
10.1038/s41598-026-38565-w · 2026 · External reference
Disease activity and hyperuricemia predict the development of cardiovascular events in patients with psoriatic arthritis: Results of the 10-year prospective evaluation in the CARMA cohort
10.1016/j.semarthrit.2026.152923 · 2026 · External reference
The metabolic score for insulin resistance predicts the risk of cardiovascular disease in patients with psoriatic arthritis: Results from the 10-year prospective CARMA cohort
10.1136/rmdopen-2024-005352 · 2025 · External reference
Incidence and management of cardiovascular risk factors in psoriatic arthritis and rheumatoid arthritis: A population-based study
10.1002/acr.23094 · 2017 · External reference
On the HUNT for cardiovascular risk factors and disease in patients with psoriatic arthritis: Population-based data from the Nord-Trøndelag Health Study
10.1136/annrheumdis-2014-206824 · 2016 · External reference
Systematic review and meta-analysis on prevalence of metabolic syndrome in psoriatic arthritis, rheumatoid arthritis and psoriasis
10.1111/1756-185x.14147 · 2021 · External reference
Increased burden of inflammation over time is associated with the extent of atherosclerotic plaques in patients with psoriatic arthritis
10.1136/annrheumdis-2014-205267 · 2015 · External reference
High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors
10.1002/art.22884 · 2007 · External reference
Cardiovascular risk markers in patients with psoriatic arthritis: A meta-analysis of literature studies
10.3109/07853890.2015.1068950 · 2015 · External reference
The Framingham Risk Score underestimates the extent of subclinical atherosclerosis in patients with psoriatic disease
10.1136/annrheumdis-2013-203433 · 2014 · External reference
Disease activity influences cardiovascular risk reclassification based on carotid ultrasound in patients with psoriatic arthritis
10.3899/jrheum.190729 · 2020 · External reference
Cardiovascular risk reclassification according to six cardiovascular risk algorithms and carotid ultrasound in psoriatic arthritis patients
10.1007/s10067-021-06002-0 · 2022 · External reference
Role of carotid ultrasound and Systematic Coronary Risk Evaluation charts for the cardiovascular risk stratification of patients with psoriatic arthritis
10.3899/jrheum.181223 · 2020 · External reference
The predictive accuracy of cardiovascular disease risk prediction tools in inflammatory arthritis and psoriasis: An observational validation study using the Clinical Practice Research Datalink
10.1093/rheumatology/kead610 · 2024 · External reference
EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update
10.1136/annrheumdis-2016-209775 · 2017 · External reference
High prevalence of subclinical atherosclerosis in psoriatic arthritis patients: A study based on carotid ultrasound
10.1007/s00296-016-3617-x · 2017 · External reference
Cost-efficiency of imaging strategies for detecting subclinical atherosclerosis in psoriatic arthritis
10.1007/s10067-025-07797-y · 2026 · External reference
10.3390/biomedicines14061395
10.3390/biomedicines14061395 · External reference
Prevalence and severity of coronary artery disease linked to prognosis in psoriasis and psoriatic arthritis patients: A multi-centre cohort study
10.1111/joim.13311 · 2021 · External reference
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
10.1093/eurheartj/ehab484 · 2021 · External reference
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
10.1093/eurheartj/ehaf190 · 2025 · External reference
The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: A systematic review and meta-analysis
10.1136/annrheumdis-2014-206624 · 2015 · External reference
The effect of TNF inhibitors on cardiovascular events in psoriasis and psoriatic arthritis: An updated meta-analysis
10.1007/s12016-016-8560-9 · 2016 · External reference
Association of tumor necrosis factor inhibitor treatment with reduced indices of subclinical atherosclerosis in patients with psoriatic disease
10.1002/art.40366 · 2018 · External reference
Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: A meta-analysis of randomised controlled trials
10.1136/rmdopen-2018-000763 · 2019 · External reference
Impact of targeted therapies on the risk of cardiovascular events in patients with psoriasis and psoriatic arthritis: A systematic review and aggregate data meta-analysis of randomized controlled trials
10.1111/1756-185x.14603 · 2023 · External reference
Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: A nationwide cohort study
10.1093/rheumatology/keab522 · 2022 · External reference
Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis
10.1056/nejmoa2109927 · 2022 · External reference
Risk of major adverse cardiovascular events and thromboembolism events in patients with psoriatic arthritis on JAK inhibitors: A network meta-analysis
10.1007/s40744-025-00783-5 · 2025 · External reference
Management of psoriatic arthritis in patients with comorbidities: An updated literature review informing the 2021 GRAPPA treatment recommendations
2023 · External reference
Risk of cardiovascular morbidity in patients with psoriatic arthritis: A meta-analysis of observational studies
10.1002/acr.22926 · ExternalCitation · doi-reference
Incidence and management of cardiovascular risk factors in psoriatic arthritis and rheumatoid arthritis: A population-based study
10.1002/acr.23094 · ExternalCitation · doi-reference
High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors
10.1002/art.22884 · ExternalCitation · doi-reference
Association of tumor necrosis factor inhibitor treatment with reduced indices of subclinical atherosclerosis in patients with psoriatic disease
10.1002/art.40366 · ExternalCitation · doi-reference
High prevalence of subclinical atherosclerosis in psoriatic arthritis patients: A study based on carotid ultrasound
10.1007/s00296-016-3617-x · ExternalCitation · doi-reference
Comorbidities in psoriatic arthritis: A systematic review and meta-analysis
10.1007/s00296-020-04775-2 · ExternalCitation · doi-reference
Cardiovascular risk reclassification according to six cardiovascular risk algorithms and carotid ultrasound in psoriatic arthritis patients
10.1007/s10067-021-06002-0 · ExternalCitation · doi-reference
Cost-efficiency of imaging strategies for detecting subclinical atherosclerosis in psoriatic arthritis
10.1007/s10067-025-07797-y · ExternalCitation · doi-reference
The effect of TNF inhibitors on cardiovascular events in psoriasis and psoriatic arthritis: An updated meta-analysis
10.1007/s12016-016-8560-9 · ExternalCitation · doi-reference
Risk of major adverse cardiovascular events and thromboembolism events in patients with psoriatic arthritis on JAK inhibitors: A network meta-analysis
10.1007/s40744-025-00783-5 · ExternalCitation · doi-reference
Cardiovascular risk in psoriatic arthritis: How can we manage it?
10.1016/j.autrev.2025.103889 · ExternalCitation · doi-reference
Disease activity and hyperuricemia predict the development of cardiovascular events in patients with psoriatic arthritis: Results of the 10-year prospective evaluation in the CARMA cohort
10.1016/j.semarthrit.2026.152923 · ExternalCitation · doi-reference
Psoriatic arthritis
10.1038/s41572-021-00293-y · ExternalCitation · doi-reference
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Updated treatment recommendations for psoriatic arthritis 2021
10.1038/s41584-022-00798-0 · ExternalCitation · doi-reference
Excess cardiovascular morbidity in psoriatic arthritis and cardioprotective effects of biologic DMARDs: A propensity-matched analysis
10.1038/s41598-026-38565-w · ExternalCitation · doi-reference
Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis
10.1056/nejmoa2109927 · ExternalCitation · doi-reference
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
10.1093/eurheartj/ehab484 · ExternalCitation · doi-reference
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
10.1093/eurheartj/ehaf190 · ExternalCitation · doi-reference
Patterns and risk of cardiovascular disease in rheumatoid arthritis and psoriatic arthritis: A nationwide cohort study in the UK
10.1093/rap/rkag016 · ExternalCitation · doi-reference
Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: A nationwide cohort study
10.1093/rheumatology/keab522 · ExternalCitation · doi-reference
The predictive accuracy of cardiovascular disease risk prediction tools in inflammatory arthritis and psoriasis: An observational validation study using the Clinical Practice Research Datalink
10.1093/rheumatology/kead610 · ExternalCitation · doi-reference
Risk of cardiovascular disease decreases over time in psoriatic arthritis but not in spondylarthritis: Meta-analysis of longitudinal studies
10.1093/rheumatology/keae080 · ExternalCitation · doi-reference
Systematic review and meta-analysis on prevalence of metabolic syndrome in psoriatic arthritis, rheumatoid arthritis and psoriasis
10.1111/1756-185x.14147 · ExternalCitation · doi-reference
Impact of targeted therapies on the risk of cardiovascular events in patients with psoriasis and psoriatic arthritis: A systematic review and aggregate data meta-analysis of randomized controlled trials
10.1111/1756-185x.14603 · ExternalCitation · doi-reference
Prevalence and severity of coronary artery disease linked to prognosis in psoriasis and psoriatic arthritis patients: A multi-centre cohort study
10.1111/joim.13311 · ExternalCitation · doi-reference
Cardiovascular comorbidities in patients with psoriatic arthritis: A systematic review
10.1136/annrheumdis-2011-201194 · ExternalCitation · doi-reference
The Framingham Risk Score underestimates the extent of subclinical atherosclerosis in patients with psoriatic disease
10.1136/annrheumdis-2013-203433 · ExternalCitation · doi-reference
Increased burden of inflammation over time is associated with the extent of atherosclerotic plaques in patients with psoriatic arthritis
10.1136/annrheumdis-2014-205267 · ExternalCitation · doi-reference
Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: A population-based cohort study
10.1136/annrheumdis-2014-205675 · ExternalCitation · doi-reference
The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: A systematic review and meta-analysis
10.1136/annrheumdis-2014-206624 · ExternalCitation · doi-reference
On the HUNT for cardiovascular risk factors and disease in patients with psoriatic arthritis: Population-based data from the Nord-Trøndelag Health Study
10.1136/annrheumdis-2014-206824 · ExternalCitation · doi-reference
Incidence and predictors for cardiovascular events in patients with psoriatic arthritis
10.1136/annrheumdis-2015-207980 · ExternalCitation · doi-reference
EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update
10.1136/annrheumdis-2016-209775 · ExternalCitation · doi-reference
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update
10.1136/ard-2024-225531 · ExternalCitation · doi-reference
Cardiovascular morbidity in psoriatic arthritis
10.1136/ard.2008.094839 · ExternalCitation · doi-reference
Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: A meta-analysis of randomised controlled trials
10.1136/rmdopen-2018-000763 · ExternalCitation · doi-reference
The metabolic score for insulin resistance predicts the risk of cardiovascular disease in patients with psoriatic arthritis: Results from the 10-year prospective CARMA cohort
10.1136/rmdopen-2024-005352 · ExternalCitation · doi-reference
Cardiovascular comorbidities in psoriatic arthritis: State of the art
10.1177/1759720x241274537 · ExternalCitation · doi-reference
SANRA—A scale for the quality assessment of narrative review articles
10.1186/s41073-019-0064-8 · ExternalCitation · doi-reference
Cardiovascular risk markers in patients with psoriatic arthritis: A meta-analysis of literature studies
10.3109/07853890.2015.1068950 · ExternalCitation · doi-reference
10.3390/biomedicines14061395
10.3390/biomedicines14061395 · ExternalCitation · doi-reference
10.3390/ijms27104226
10.3390/ijms27104226 · ExternalCitation · doi-reference
Role of carotid ultrasound and Systematic Coronary Risk Evaluation charts for the cardiovascular risk stratification of patients with psoriatic arthritis
10.3899/jrheum.181223 · ExternalCitation · doi-reference
Disease activity influences cardiovascular risk reclassification based on carotid ultrasound in patients with psoriatic arthritis
10.3899/jrheum.190729 · ExternalCitation · doi-reference
